Plain-English translation of NCT06176729 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether polatuzumab vedotin combined with two other medications works well for older adults who are frail or weak and have just been diagnosed with diffuse large B cell lymphoma, a serious blood cancer. The three medications work together to attack cancer cells. Researchers want to see if this combination is safe and effective for patients who might not be strong enough to handle harsher standard treatments.
Many elderly patients with this aggressive lymphoma are too frail or weak for the strongest standard treatments, which can be very hard on the body. This trial exists to find out whether this medication combination can work better for these patients while being easier to tolerate.
You likely qualify if…
You likely don't qualify if…
You will receive the three-drug treatment combination every 21 days. The first two drugs are given by IV infusion on day one of each cycle, and the third is taken as a pill by mouth from days one through fourteen. After four cycles, doctors will check how well the treatment is working. If your cancer responds well, you'll continue for four more cycles. If it isn't working, you'll stop the study treatment and receive other care options instead.
AI-generated summary from trial data · Aug 5, 2026 · Not medical advice
China
Phase
Testing effectiveness
Sponsor
Yan Zhang, MD
Collaborators
Peking University Third Hospital, Peking University First Hospital
Enrollment target
~30 participants
Started
October 2023
Primary completion
October 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
70 Years and older
Last updated on clinicaltrials.gov in December 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wei Wang, MD
Peking Union Medical College Hospital
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.